Trial Profile
Safety and Efficacy of Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Sep 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib; Dexamethasone; Thalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 16 Sep 2016 New trial record